Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Considerations for Selection and Use of Frontline Therapy in Mantle Cell Lymphoma

December 23rd 2021

Shared insight on the optimal selection and use of frontline therapy for patients who present with mantle cell lymphoma.

An Overview of Mantle Cell Lymphoma and Frontline Therapy

December 23rd 2021

Expert panelists discuss a number of recent updates in B-cell lymphoma, particularly mantle cell lymphoma, follicular lymphoma and marginal zone lymphoma, that were presented at key conferences in 2021.

Diffuse Large B-Cell Lymphoma Overview: An Aggressive Heterogenous Disease

December 23rd 2021

A panel of oncologists talks about diffuse large B-cell lymphoma, what patient and disease factors one should take into account when thinking about DLBCL.

Choosing the Appropriate Treatment Strategy in CLL

December 22nd 2021

Nitin Jain, MD, shares factors to consider when selecting the optimal therapy for patients with CLL.

Clinical Case 1: 69-Year-Old Man With Multiple Myeloma (MM)

December 22nd 2021

Expert hematologist/oncologists review the case of a 69-year-old man with multiple myeloma who had a biochemical relapse and share their approaches to treatment.

Using Noncovalent BTK Inhibitors for the Management of CLL

December 22nd 2021

Nitin Jain, MD, provides insight on approaching treatment with noncovalent BTK inhibitors for patients with CLL who have acquired resistance to covalent inhibitors.

Adaptation Is Key to Advancing Care for Adult Patients With Leukemia

December 21st 2021

Jorge E. Cortes, MD, has been an investigative leader for nearly 30 years in the development of numerous leukemia treatments.

Emerging Agents for R/R MZL

December 21st 2021

Drs. Alexey Danilov and Tycel Jovelle Phillips share insight on emerging agents and future directions for the management of marginal zone lymphoma.

Selecting the Appropriate Treatment in R/R MZL

December 21st 2021

Alexey Danilov, MD, and Tycel Jovelle Phillips, MD, discuss strategies for selecting the appropriate treatment for patients with relapsed/refractory marginal zone lymphoma.

FDA Approval Offers Hope for Prevention of Acute Graft-Versus-Host Disease

December 21st 2021

Approval of the drug abatacept opens up bone marrow transplant as an option for many more patients with cancer or blood disorders — especially patients of diverse ethnicities, who have extra difficulty finding a good match

Rapid Readouts: Interim Analysis Results From the Phase 2 PRIMO Trial in R/R Peripheral T-Cell Lymphoma

December 20th 2021

Jonathan E. Brammer, MD, reports data presented at the 2021 American Society of Hematology Annual Meeting regarding interim analysis study results from the phase 2 PRIMO trial evaluating the use of duvelisib monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma.

Red Blood Cells Stored in Hypoxic State Show Lower Adhesion Levels Vs Normoxia

December 17th 2021

Red blood cells processed and stored in a hypoxic state maintain their integrity, which may reduce the risk of developing vaso-occlusion after red blood cell transfusion.

Dr. Mouhieddine on Outcomes After Bispecific Antibodies in R/R Multiple Myeloma

December 17th 2021

Tarek H. Mouhieddine, discusses a study that evaluated outcomes in patients with relapsed/refractory multiple myeloma who progressed on bispecific antibodies.

Dr. Daver on the Next Steps for Menin Inhibitors in AML

December 17th 2021

Naval Daver, MD, discusses the next steps for menin inhibitors in acute myeloid leukemia.

Itolizumab May Minimize Incidence of aGVHD Following HSCT, Improve Outcomes

December 16th 2021

Itolizumab showed the potential to decrease the response of host T cells to a donor graft, minimize the incidence of acute graft-vs-host disease following hematopoietic stem cell transplantation, and improve outcomes for these patients.

KO-539 Shows Synergistic Activity With Several Targeted Agents in KMT2A-Rearranged and NPM1-Mutant AML Models

December 15th 2021

Preclinical evidence suggests that pairing KO-539 with targeted agents directed against BCL-2, BET, and CDK6 could result in superior efficacy against KMT2A-rearranged and NPM1-mutated acute myeloid leukemia.

APVO436 Demonstrates Manageable Safety With Anti-Neoplastic Activity in Relapsed/Refractory AML/MDS

December 15th 2021

The investigational bispecific antibody APVO436 demonstrated tolerability with encouraging anti-neoplastic efficacy in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome, according to updated findings from an ongoing phase 1 trial.

Amphiregulin Represents Potentially Predictive Biomarker in Acute GVHD

December 15th 2021

Elevated amphiregulin was associated with increased mortality risk in acute graft–versus-host-disease, according to a sample of 2 prospective clinical trials showed.

CRS and Interventional Steroids Bare No Adverse Effect on Outcomes With the CD3/CD123 Bispecific Antibody APVO436 in AML/MDS

December 15th 2021

Treatment with the CD123- and CD3-engaging bispecific antibody APVO436 caused cytokine release syndrome in approximately 1 of 5 patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome but was generally well managed with steroids.

FDA Approves Abatacept for the Prevention of Acute GVHD

December 15th 2021

The FDA has approved abatacept for the prophylaxis of acute graft-versus-host disease, in combination with certain immunosuppressants.